Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00.
• On Monday, June 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00.

Gilead Sciences Trading Up 3.1%

NASDAQ GILD traded up $4.10 on Tuesday, hitting $135.25. 10,084,002 shares of the company were exchanged, compared to its average volume of 7,149,559. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The firm has a market capitalization of $167.92 billion, a P/E ratio of 18.43 and a beta of 0.32. The company’s 50 day moving average price is $129.55 and its 200-day moving average price is $136.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.26) by $0.51. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2026 guidance at -0.650–0.300 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported a quarterly loss of $6.75 per share, which was better than analysts’ expected loss of approximately $7.07–$7.26 per share. Product sales increased 8% year over year and exceeded Wall Street estimates, providing support for the shares. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: HIV medicines delivered double-digit sales growth. Yeztugo, Gilead’s newer HIV pre-exposure prophylaxis drug, narrowly beat sales expectations, keeping attention on its potential to become a major long-term growth driver. Gilead’s High-Profile HIV Drug Beat
• Positive Sentiment: California’s highest court ruled in Gilead’s favor in a product-liability case, finding that drugmakers do not have a legal duty to develop an even safer alternative when an existing medicine is considered safe. The decision reduces a potentially significant legal risk. California Court Rules for Gilead
• Neutral Sentiment: Gilead posted a quarterly loss because of costs associated with recent acquisitions, although its underlying operating performance benefited from stronger HIV demand. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Management lowered its full-year Veklury forecast after sales of the COVID-19 treatment plunged 81% in the quarter. This highlights continuing pressure on a legacy revenue stream. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: Full-year revenue guidance of $30.1 billion to $30.4 billion is below the $30.5 billion analyst consensus, which may limit enthusiasm despite better-than-expected EPS guidance. AIDS Healthcare Foundation also criticized Gilead’s pricing and business practices, adding reputational pressure. AHF Crowns Gilead Corporate Welfare King

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at $26,000. Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Truist Financial dropped their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Barclays cut their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $157.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.